Problems of Delivery of Monoclonal Antibodies: Pharmaceutical and Pharmacokinetic Solutions

Clinical Pharmacokinetics

Volumn 28, Issue 2, 1995, Pages 126-142

  Reilly, Raymond M ^a,b   Sandhu, Jasbir ^a   Alvarez Diez, Teresa M ^a   Gallinger, Steven ^a   Kirsh, Joel ^a   Stern, Hartley ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; BLOOD VESSEL PERMEABILITY; CANCER; CHEMICAL BOND; CLINICAL TRIAL; CROSS REACTION; DRUG ADMINISTRATION; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG METABOLISM; DRUG TARGETING; DRUG THERAPY; DRUG UPTAKE; GENETIC ENGINEERING; HUMAN; IMMUNOGENICITY; INTRAPERITONEAL DRUG ADMINISTRATION; PHARMACEUTICS; PHARMACOKINETICS; PRIORITY JOURNAL; REGIONAL PERFUSION; REVIEW; TUMOR VASCULARIZATION;

ANIMAL; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, NEOPLASM; CAPILLARY PERMEABILITY; CROSS REACTIONS; DRUG DELIVERY SYSTEMS; HUMAN; IMMUNOCONJUGATES; IMMUNOGLOBULIN FRAGMENTS; MICE; NEOPLASMS; SUPPORT, NON-U.S. GOV'T;

EID: 0028878938     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-199528020-00004     Document Type: Review

References (131)

1. Comparative dual label study of first and second generation antitumor-associated glycoprotein-72 monoclonal antibodies in colorectal cancer patients
2. Clinical comparison of radiolocalization of two monoclonal antibodies (mAbs) against the TAG-72 antigen
3. Colorectal tumors: scintigraphy with In-111 anti-CEA monoclonal antibody and correlation with surgical, histopathologic and immunohistochemical findings
4. Patient biodistribution of intraperitoneally administered yttrium-90-labeled antibody
5. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate
6. Disposition of a murine monoclonal antibody vinca conjugate (KS1/4-DAVLB) in patients with adenocarcinomas
7. Use of radiolabelled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancer by external photoscanning
8. Continuous cultures of fused cells secreting antibody of pre-defined specificity
9. Compartmental analysis of the pharmacokinetics of radioiodinated monoclonal antibody B72.3 in colon cancer patients
10. 111in-labeled OC-125 antibody in cancer patients compared with the 19-9 antibody
11. 111in-labeled 260F9 anti-(breast cancer) antibody in patients
12. Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG, k 17-1A monoclonal antibody
13. Improved pharmacokinetics and tumor localization of immunotoxins constructed with the Mr 30,000 form of ricin A chain
14. Radioimmunotherapy of malignancies
15. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors
16. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies
17. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure
18. Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3
19. Quantitative analyses of selective radiolabeled monoclonal antibody localization in metastatic lesions of colorectal cancer patients
20. Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33
21. The effect of tumor CEA content and tumor size on tissue uptake of indium 111-labeled anti-CEA monoclonal antibody
22. Regional heterogeneity and complementation of the expression of the tumor-associated glycoprotein 72 epitopes in colorectal cancer
23. A modeling analysis of monoclonal antibody percolation through tumors: a binding site barrier
24. An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a ‘binding site barrier’
25. Transport of fluid and macromolecules in tumors III: role of binding and metabolism
26. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier
27. Tumor size: effect on monoclonal antibody uptake in tumor models
28. Tumor uptake as a function of tumor mass: a mathematical model
29. Effect of tumor mass and antigenic nature on the biodistribution of labeled monoclonal antibodies in mice
30. Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies
31. Mechanisms of tissue uptake and metabolism of radiolabeled antibody-role of antigen: antibody complex formation
32. Approaches to radiolabeling of antibodies for diagnosis and therapy of cancer
33. The preparation of DTPA-coupled antibodies radiolabeled with metallic radionuclides: an improved method
34. Pharmacokinetics of an indium-111-labeled monoclonal antibody in cancer patients
35. In vitro stability of EDTA and DTPA immunoconjugates of monoclonal antibody 2G3 labeled with indium-111
36. Comparative biodistributions of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts
37. Intracellular metabolism of indium-111-DTPA labeled receptor targeted proteins
38. Processing of antibodyradioisotope conjugates after binding to the surface of tumor cells
39. Differences in experimental tumor localization of dual-labeled monoclonal antibody
40. Differences in biodistribution of indium-111- and iodine-131-labeled B72.3 monoclonal antibodies in patients with colorectal cancer
41. m-labelled monoclonal antibodies: a review
42. m directly labelled to an Fab’ antibody via stannous ion and mercaptoethanol reduction
43. m
44. Development and biological evaluation of a kit for preformed chelate technetium-99m radiolabeling of an antibody Fab fragment using a diamide dimercaptide chelating agent
45. Endocytosis and intracellular routing of an antibody-ricin A chain conjugate
46. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy
47. The characteristics of blood-borne radiolabels and the effect of anti-mouse IgG antibodies on localization of radiolabeled monoclonal antibody in cancer patients
48. Imaging of tumor in patients with indium-111-labeled biotin and streptavidin conjugated antibodies: preliminary communication
49. Immunogenicity in rabbits and mice of an antibody-chelate conjugate: comparison of (S) and (R) macrocyclic enantiomers and an acyclic chelating agent
50. Intracavitary use of two radiolabeled tumor-associated monoclonal antibodies
51. Peritoneal carcinomatosis: imaging with intraperitoneal injection of I-131-labeled B72.3 monoclonal antibody
52. Biodistribution of antibodies after intraperitoneal or intravenous injection and effect of carbohydrate modifications
53. Exchange of macromolecules between plasma and peritoneal cavity in ascites tumor-bearing, normal, and serotonin-injected mice
54. 131I radiotherapy
55. Localization of radioiodine conjugated to the monoclonal antibody HMFG2 in human ovarian carcinoma: assessment of intravenous and intraperitoneal routes of administration
56. Improved radiolabeled monoclonal antibody uptake by lavage of intraperitoneal carcinomatosis in mice
57. Immunolymphoscintigraphy for the detection of lymph node metastases from breast cancer
58. 99mTc-labeled monoclonal antibody (BW 431/26) reacting with carcinoembryonic antigen in breast cancer
59. Kinetics of interstitially administered monoclonal antibodies for purposes of lymphoscintigraphy
60. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab’)2 and Fab’ in mice
61. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms
62. Engineering of antibodies
63. Man-made antibodies
64. Single chain antibody (SCA) encoding genes: one-step construction and expression in eukaryotic cells
65. Production of murine V-human Cr1 chimeric anti-TAG72 antibody using V region cDNA amplified by PCR
66. Renaturation, purification and characterization of recombinant Fab-fragments produced in Escherichia coli
67. Expression of functional antibody Fv and Fab fragments in Escherichia coli
68. Production of antibodies in transgenic plants
69. Recombinant toxins for cancer treatment
70. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli
71. Expression of an antibody Fv fragment in myeloma cells
72. A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen
73. B3(fv)-PE 38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice
74. Development of biologically active peptides based on antibody structure
75. Anti-antibody enhancement of iodine-131 anti-CEA radioimmunodetection in experimental and clinical studies
76. 131I-labeled murine monoclonal antibody from patients’ blood by intravenous human anti-murine immunoglobulin antibody
77. 131I-labeled antibody to carcinoembryonic antigen in cancer radioimmunotherapy
78. Plasmapheresis in radioimmunotherapy of micrometastases: a mathematical modeling and dosimetrical analysis
79. A general, extracorporeal immunoadsorption method to increase the tumor-to-normal tissue ratio in radioimmunoimaging and radioimmunotherapy
80. Two-step targeting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin
81. Rapid blood clearance of biotinylated IgG after infusion of avidin
82. Intraperitoneal radio-localization of tumors pre-targeted by biotinylated monoclonal antibodies
83. Three-step monoclonal antibody tumor targeting in CEA positive patients
84. 99mTc]PnAO-biotin
85. Immunoscintigraphy with three step monoclonal pre-targeting technique in diagnosis of uveal melanoma: preliminary results
86. In-vitro and in-vivo evaluation of streptavidin immunoconjugates of the second generation TAG-72 monoclonal antibody CC49
87. Disulfide bond-targeted radiolabeling: tumor specificity of a streptavidin-biotinylated monoclonal antibody complex
88. 111In-labeled biotin
89. Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor
90. Pharmacokinetic analysis of two-step approaches using bifunctional enzyme-conjugated antibodies
91. A distributed pharmacokinetic model of two-step imaging and treatment protocols
92. Antibodies against metal chelates
93. Pre-targeted immunoscintigraphy of murine tumors with indium-111 labeled bifunctional haptens
94. A new approach to the problem of targeting specific monoclonal antibodies to human tumors using antihapten chimeric antibodies
95. Specific recognition of antibody-oligonucleotide conjugates by radiolabeled antisense nucleotides: a novel approach for two-step radioimmunotherapy of cancer
96. In vitro evaluation of DNA-DNA hybridization as a two-step approach in radioimmunotherapy of cancer
97. Monoclonal antibodies as reversible equilibrium carriers of radiopharmaceuticals
98. Antibody-directed enzyme prodrug therapy
99. Genetic construction, expression and characterization of a single chain anti-carcinoma antibody fused to beta-lactamase
100. Intratumoural generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine
101. Galactosylated antibodies and antibody-enzyme conjugates in ADEPT
102. Biodistribution and histological localization of anti-human colon cancer monoclonal antibody (MAb) 1A3: the influence of administered MAb dose on tumor uptake
103. Effect of antibody dose on the imaging and biodistribution of indium-111 9.2.27 anti-melanoma monoclonal antibody
104. Effect of seven vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumors
105. Vascular permeability and interstitial diffusion of macromolecules in the hamster cheek pouch: effects of vasoactive drugs
106. Generation and characterization of B72.3 second-generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen
107. Radioimmunolocalization of human carcinoma xenografts with B72.3 second-generation monoclonal antibodies
108. Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates
109. Metabolism of indium chelates attached to monoclonal antibody: minimal transchelation of indium from benzyl-EDTA chelate in-vivo
110. Pharmacokinetics in patients of an anti-carcinoembryonic antigen antibody radiolabeled with indium-111 using a novel diethylenetriamine pentaacetic acid chelator
111. Improved sarcoma imaging and reduced hepatic activity with indium-111-SCNBz-DTPA linked to MoAb 19–24
112. 111In labelling technique in patients with recurrent colon cancer
113. Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent
114. A method for the radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine
115. Chelate radio-chemistry: cleavable linkers lead to altered levels of radioactivity in the liver
116. Reduction of background activities by introduction of a diester linkage between antibody and a chelate in radioimmunodetection of tumor
117. 111In-DTPA to accelerate clearance from non-target organs and blood
118. Production of functional chimeric mouse/human antibody
119. Chimeric human antibody molecules: mouse antigen domains with human constant region domains
120. Transfer of a cloned immunoglobulin light-chain gene to mutant hybridoma cells restores specific antibody production
121. Functional immunoglobulin M production after transfection of cloned immunoglobulin heavy and light genes into lymphoid cells
122. Rhenium-186-labeled chimeric antibody NR-LU-13: pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10
123. Production of a mousehuman chimeric monoclonal antibody to CD20 with potent Fc-dependent biological activity
124. Biological activity of human-mouse IgG1, IgG2, IgG3 and IgG4 chimeric monoclonal antibodies with anti-tumor specificity
125. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response
126. Similar idiotypic specificities in immunoglobulin fractions with different antibody functions or even without detectable antibody function
127. Replacing the complementarity-determining regions in a human antibody with those from a mouse
128. Tumor localization with a radioactively labelled reshaped human monoclonal antibody
129. 131I-chimeric mouse/human B72.3 (human γ4) monoclonal antibody in humans
130. On immunity with special reference to cell life